MIF and cancer: C1 S100A8+ TCs acted on myeloid cells CD74-CXCR4 and CD74-CD44 receptors through MIF ligands, which might promote the transformation of normal myeloid cells into cancer-related myeloid cells and inhibit the body’s normal anti-tumor immune effect.